» Articles » PMID: 35668839

Tangled Quest of Post-COVID-19 Infection-caused Neuropathology and What 3P Nano-bio-medicine Can Solve?

Overview
Journal EPMA J
Date 2022 Jun 7
PMID 35668839
Authors
Affiliations
Soon will be listed here.
Abstract

COVID-19-caused neurological problems are the important post-CoV-2 infection complications, which are recorded in ~ 40% of critically ill COVID-19 patients. Neurodegeneration (ND) is one of the most serious complications. It is necessary to understand its molecular mechanism(s), define research gaps to direct research to, hopefully, design new treatment modalities, for predictive diagnosis, patient stratification, targeted prevention, prognostic assessment, and personalized medical services for this type of complication. Individualized nano-bio-medicine combines nano-medicine (NM) with clinical and molecular biomarkers based on omics data to improve during- and post-illness management or post-infection prognosis, in addition to personalized dosage profiling and drug selection for maximum treatment efficacy, safety with least side-effects. This review will enumerate proteins, receptors, and enzymes involved in CoV-2 entrance into the central nervous system (CNS) via the blood-brain barrier (BBB), and list the repercussions after that entry, ranging from neuroinflammation to neurological symptoms disruption mechanism. Moreover, molecular mechanisms that mediate the host effect or viral detrimental effect on the host are discussed here, including autophagy, non-coding RNAs, inflammasome, and other molecular mechanisms of CoV-2 infection neuro-affection that are defined here as hallmarks of neuropathology related to COVID-19 infection. Thus, a couple of questions are raised; for example, "What are the hallmarks of neurodegeneration during COVID-19 infection?" and "Are epigenetics promising solution against post-COVID-19 neurodegeneration?" In addition, nano-formulas might be a better novel treatment for COVID-19 neurological complications, which raises one more question, "What are the challenges of nano-bio-based nanocarriers pre- or post-COVID-19 infection?" especially in the light of omics-based changes/challenges, research, and clinical practice in the framework of predictive preventive personalized medicine (PPPM / 3P medicine).

Citing Articles

Multiomics as instrument to promote 3P medical approaches for the overall management of respiratory syncytial viral infections.

Bajinka O, Ouedraogo S, Li N, Zhan X EPMA J. 2025; 16(1):217-238.

PMID: 39991100 PMC: 11842696. DOI: 10.1007/s13167-024-00395-z.


Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.

Chang H, Chen E, Hu Y, Wu L, Deng L, Ye-Lehmann S Adv Sci (Weinh). 2023; 11(10):e2305554.

PMID: 38143270 PMC: 10933635. DOI: 10.1002/advs.202305554.


Long COVID as a Tauopathy: Of "Brain Fog" and "Fusogen Storms".

Sfera A, Rahman L, Del Campo C, Kozlakidis Z Int J Mol Sci. 2023; 24(16).

PMID: 37628830 PMC: 10454863. DOI: 10.3390/ijms241612648.


Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with and validation.

Wang Q, Liu Y, Li Z, Tang Y, Long W, Xin H Front Immunol. 2023; 14:1182277.

PMID: 37215115 PMC: 10196375. DOI: 10.3389/fimmu.2023.1182277.

References
1.
Skladany L, Koller T, Selcanova S, Vnencakova J, Jancekova D, Durajova V . Challenging management of severe chronic disorders in acute pandemic situation: Chronic liver disease under COVID-19 pandemic as the proof-of-principle model to orchestrate the measures in 3PM context. EPMA J. 2021; 12(1):1-14. PMC: 7926196. DOI: 10.1007/s13167-021-00231-8. View

2.
Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne R, Goldman J . COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020; 6:18. PMC: 7441399. DOI: 10.1038/s41531-020-00123-0. View

3.
Young M, OHare M, Matiello M, Schmahmann J . Creutzfeldt-Jakob disease in a man with COVID-19: SARS-CoV-2-accelerated neurodegeneration?. Brain Behav Immun. 2020; 89:601-603. PMC: 7362815. DOI: 10.1016/j.bbi.2020.07.007. View

4.
Gharbavi M, Amani J, Kheiri-Manjili H, Danafar H, Sharafi A . Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier. Adv Pharmacol Sci. 2019; 2018:6847971. PMC: 6311792. DOI: 10.1155/2018/6847971. View

5.
Akilli N, Yosunkaya A . Part of the Covid19 puzzle: Acute parkinsonism. Am J Emerg Med. 2021; 47:333.e1-333.e3. PMC: 7903921. DOI: 10.1016/j.ajem.2021.02.050. View